Clinical Trials

NCT Number: NCT04986423 Phase: Phase 2 Trial Summary: This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Zenith Epigenetics Acronym:

NCT Number: NCT05011188 Phase: Phase 1|Phase 2 Trial Summary: This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym:

NCT Number: NCT05700669 Phase: PHASE1|PHASE2 Trial Summary: This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combinati – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Valerio Therapeutics Acronym:

NCT Number: NCT05502315 Phase: Phase 2 Trial Summary: This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rana McKay, MD Acronym: CANOPY

NCT Number: NCT05683964 Phase: Early Phase 1 Trial Summary: The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antig – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Beth Israel Deaconess Medical Center Acronym:

NCT Number: NCT04335682 Phase: Phase 2 Trial Summary: This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer (mCRPC – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Alliance Foundation Trials, LLC. Acronym: ARACOG

NCT Number: NCT04337580 Phase: Phase 2 Trial Summary: The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Inve – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Wake Forest University Health Sciences Acronym: FASN

NCT Number: NCT05751941 Phase: Phase 2 Trial Summary: This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the trea – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Acronym:

NCT Number: NCT05869682 Phase: PHASE2 Trial Summary: This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant pa – clinicaltrials.gov for more information and locations […]

NCT Number: NCT04346225 Phase: Phase 2 Trial Summary: This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym: